# Timely access to novel therapies:

Can Canada's multi-payer system be inspired by international approaches for managing evidence uncertainty related to value while providing patients with timely access to life-saving therapies?

2CSENSE CADTH Symposium Panel Session May 18, 2023



### Moderator



**Allison Wills** 

PARTNER, **20SENSE**; CO-CHAIR OF THE REAL-WORLD EVIDENCE AND OUTCOMES-BASED AGREEMENTS WORKING GROUP.

#### Disclosure

I have the following relevant financial relationships to disclose:

- Employed by 20Sense, which is a Canadian pharmaceutical consulting company.
- Co-chair of the Real-World Evidence and Outcomes-Based Agreements Working Group, which receives research support from members. Members currently include AbbVie, AstraZeneca, Janssen, Pfizer and Roche.


## Why discuss timely access to novel therapies while managing evidence uncertainty related to value?



2023 CADTH Symposium May 18,2023



#### 1. Increasing challenges with access




#### **Phase II Data**

# Phase II data are increasingly being used as primary evidence for public reimbursement, particularly for oncology drugs.

- In some cases, randomized trials are not possible when the patient populations under study are too rare.<sup>1</sup>
- HTA entities may struggle to determine the value of products with phase II data, and therefore making recommendations is more challenging.<sup>1</sup>
- When compared with HTA submissions for public reimbursement having phase III data, oncology drug submissions with phase II data are less likely to be recommended by CADTH.<sup>2</sup>

1. <u>CANCER TREATMENT: CANADIANS DON'T HAVE ACCESS THEY EXPECT AND DESERVE</u>, ONCOLOGY MEDICINE ACCESS ROUNDTABLE, A.DUBUC, APR. 2022. 2. Y.Y.R. LI, MD, ET AL., <u>REIMBURSEMENT RECOMMENDATIONS FOR CANCER DRUGS</u> <u>SUPPORTED BY PHASE II EVIDENCE IN CANADA</u>, CURR ONCOL. OCT. 2020





>1.5 years


In Canada, it takes more than 1.5 years for Canadian patients to get access to a new drug in public plans.

- From NOC to first listing, access to oncology therapies takes approx. 580 days, and for orphan drugs 670 days.
- Canada is among the slowest of the OECD20 countries to reimburse innovative new medicines through its public plans, based on the time from first global launch to public reimbursement (18<sup>th</sup> of 20; 926 days vs. median of 519 days).





# Increasing challenges with access International approaches to managed access



# **1** or more early access pathway

Many countries, including England and Wales, France, Germany, Italy, and Australia, have established pathways for publicly-funded early access, where patients can receive treatment while evidence collection is ongoing.





### Canada does not have a formalized early access program.



SOURCE: EARLY ACCESS TO INNOVATIVE MEDICINES, MEDLIOR HEALTH OUTCOMES RESEARCH LTD., CORD CONFERENCE PRESENTATION, MAR. 2023.



86%

### England's experience with managed access agreements<sup>1</sup>:

- 86% (19 out of 22) of technologies re-evaluated by NICE following a period of managed access were recommended for routine use in the NHS.
- 20 out of 22 were treatments for cancer.
- While 19 out of 22 involved real-world data (RWD) for the guidance update,<sup>1</sup> when examining CDF review appraisals only, the main evidence has been from clinical trial data (21 of 24 appraisals).<sup>2</sup>

"Managed access is an established mechanism in England for early patient access to promising new treatments, where significant evidential uncertainty remains...without managed access, these technologies would most likely not have been recommended for routine use within the NHS in England."

SOURCES:


1. WHAT GOES IN MUST COME OUT: AN ANALYSIS OF NICE RECOMMENDATIONS FOR DRUGS EXITING MANAGED (EARLY) ACCESS IN ENGLAND, NICE, 2022.

2. USING ADDITIONAL DATA TO REDUCE UNCERTAINTY REGARDING ONCOLOGIC DRUGS PROVIDED THROUGH MANAGED ACCESS AGREEMENTS IN ENGLAND, PHARMACOECONOMICS, SEPT. 2022.





# Increasing challenges with access International approaches to managed access The current Canadian approach





#### Quebec's 2017-2027 life sciences strategy

- Outlines objectives to further integrate innovation into the health and social services network, including expedited access to promising new drugs.
- Enabled INESSS to take a "promise of therapeutic value" approach.
- Ongoing strategic intelligence research on timely access mechanisms and conditional reimbursement schemes

Bulletin de veille stratégique INESS	Bulletin de veille stratégique
Institution to add an appear for to each increasion of a topic of origin in spin at allows. In we place as appear is symmetic up to addition application.	fearitement is after receipter to a serie in memory atalia per weight in spit at channel for a preservation approx discusses on approximation and backs
Portrait des mécanismes d'accès précoce et des modalités conditionnelles de remboursement	Expériences et apprentissages avec les modalités conditionnelles de remboursemen
Comment statigatest tas systemes de sande et de sendors sociaus plour rembiourser et implantes des inno- sectors face à leur année maistre et de plus engles acciliente? Far de grenner buileou, http://di.ac.ponche- sur les photopaus métadoses facciós précision au Ganada, ese faras-leves et les humage, une que tor les maisfablies combinances de la combinancement proposal de la la barra de la humage. Une que tor les maisfablies combinances de la combinancement proposal de la la barra de la combinance et combinance de la combinance de la combinance de la combinancement et proposal de la la barra de la combinance et combinance et la combinance de la combinance de la combinancement et proposal de la la barra de la combinance et la combinance de la combinance de la combinancement et proposal de la la barra de la combinance et la combinance de la combinance de la combinance de la combinance de la combinance	Comment Subjectent les systèmes de santil et de services sociaux pour rembourser et implante resetters face a four arrives masses et de plus en plus accélories? Proposées dans la traisaux differences parties premantes depuis guergues décremies, IMESIS se penche sur les <b>exectéstris co</b> <b>nelles de remboursement</b> .
Challed a publie or that our control and the 2000 ar the plantation conditionate destabilitations innovations; take a constitue on document de relitivence pour la présente velle.	Construction and a sequence data sectorized construction for the finance of the mandetime, any printment of the sequence of the sectorized sect
A REFERE   In the descent process we excellent at pression is a factor of a descent process process process and and a descent process of the descent proces of the descent process of the descent process of the descent proc	A REFERENT  La conjuntati des paps de 1900 et de l'antere accegances de digta de accepta de manado de enternaciones  de des apresentes unas liberarias de la calcular de acceptances de enternaciones  de conservantes de la calcular a la calcular de acceptances de enternaciones  de conservantes de la calcular de la calcular de acceptances de la calcular de acceptances de la calcular de la calcu
Modalités de mise en marché précoces ou accélérées No de la pois de la contra la contra la contra de la contre de la contra de la contra de la contra de la cont	A NOTE: • Characteristic and states principalities to a use guidelation of 100%, poor logistic and exact posterioration a determination of the states and t
Takin dasa bashari a yali da ama ana 2010, iyo na sukasini a sharan ku sukasa basan. Ng a taraba Sakasin Saka S 2011 iyo ku tara tara ya Sakasini Millingan Sakasini Millingan Sakasini Sakasini Sakasini Sakasini (1911).	
Québec	Québe


SOURCES: 2017-2027 QUEBEC LIFE SCIENCES STRATEGY: INNOVATION COMES TO LIFE, GOVERNMENT OF QUEBEC, 2017, ACCESSED MAY 2023. ÉVOLUTION DES MODALITÉS D'ACCÈS, DE REMBOURSEMENT ET DE SOUTIEN À L'IMPLANTATION DES INNOVATIONS, INESSS WEB PAGE, ACCESSED MAY 2023.





Canada's Drug and Health Technology Agency


- Proposed process for time-limited reimbursement recommendations for drugs which receive Notice of Compliance with Conditions (NOC/c) regulatory approval.
- "Time-limited reimbursement recommendations are recommendations that would be issued in favour of reimbursement in a manner that is time-limited and contingent on a future reassessment of additional evidence that addresses the uncertainty with the comparative clinical benefit and cost-effectiveness for the drug or drug regimen under review."






# Innovative market access agreements

Given the lack of formalized managed access programs in Canada, some payers and manufacturers look to innovative market access agreements, such as outcomes-based agreements and others, to support early patient access to therapies while managing evidence uncertainty.





Can Canada's multi-payer system be inspired by international approaches for managing evidence uncertainty related to value while providing patients with timely access to life-saving therapies?



### **Panelists**



#### Sylvie Bouchard

Carole R Chambers

DIRECTOR OF DRUG EVALUATION AND TECHNOLOGY ASSESSMENT FOR REIMBURSEMENT, **INESSS** 

PHARMACY DIRECTOR, CANCER SERVICES ALBERTA HEALTH SERVICES Martine Elias

EXECUTIVE DIRECTOR, MYELOMA CANADA

#### Thomas Strong

INTERIM ASSOCIATE DIRECTOR, MANAGED ACCESS, NICE



### Disclosures

Panelists have confirmed that they have no actual or potential conflicts of interest in relation to this topic or presentation.



#### Sylvie Bouchard

Carole R Chambers

DIRECTOR OF DRUG EVALUATION AND TECHNOLOGY ASSESSMENT FOR REIMBURSEMENT, **INESSS** 

PHARMACY DIRECTOR, CANCER SERVICES ALBERTA HEALTH SERVICES Martine Elias

EXECUTIVE DIRECTOR, MYELOMA CANADA


#### Thomas Strong

INTERIM ASSOCIATE DIRECTOR, MANAGED ACCESS, NICE



## **Session Objectives**

- Discuss successes and challenges related to adapted HTA
  and listing pathways.
- 2. Explore how such approaches could be applied in the Canadian multi-payer context, to help manage evidence uncertainty related to value while providing life-saving therapies to patients.
- Identify potential solutions that could be applied in Canada.
- What immediate opportunities and next steps are there? What barriers need to be overcome?



# Managed Access – A UK perspective

Thomas Strong Associate Director – Managed Access Thursday 18 May 2023

NICE National Institute for Health and Care Excellence



#### **Medicines in England**

#### 56 Million People

National Institute of Health and Care Excellence (NICE)

#### Central Single Payer: NHS England


2021/22: £17.2B on medicines and Health Tech 2 Managed Access Funds: CDF and IMF

#### What is 'Managed Access'?



- A Managed Access Agreement (MAA) is a time limited arrangement to:
- Enable patient access while further data is collected to address key uncertainties identified by NICE
- Ensure the NHS still pays a cost-effective price, through a commercial access agreement (CAA)

#### Managed Access: An outcome-based agreement?



#### Managed Access: CDF - a success?



96% immature data39% generalisability26% treatmentduration

Median 3 years of data collection

87% clinical trial 78% RWE, however mostly supportive

#### Managed Access: CDF - a success?



96% immature data39% generalisability26% treatmentduration


Median 3 years of data collection

87% clinical trial 78% RWE, however mostly supportive

#### Managed Access: What have we learnt?



#### Managed Access: Not the answer to everything



## **Panel Discussion**

Can Canada's multi-payer system be inspired by international approaches for managing evidence uncertainty related to value while providing patients with timely access to life-saving therapies?

#### Moderator



Allison Wills

20SENSE

**Panelists** 

**Sylvie** Bouchard

INESSS



**Carole R** 

ALBERTA HEALTH

SERVICES

Chambers



Elias

MYELOMA CANADA



Thomas Strong



2023 CADTH Symposium May 18,2023

# **Audience Q&A**





# Timely access to novel therapies:

Can Canada's multi-payer system be inspired by international approaches for managing evidence uncertainty related to value while providing patients with timely access to life-saving therapies?

**2C**SENSE

CADTH Symposium

Panel Session May 18, 2023

Contact: Allison Wills, 20Sense awills@20sense.ca